Mizuho Securities Reiterates Neutral Rating on Jazz Pharmaceuticals (JAZZ)
Tweet Send to a Friend
Mizuho Securities analyst Irina Koffler reiterated a Neutral rating and $148.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) following an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
